|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Emory University |
|---|---|
| Collaborator: |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Information provided by: | Emory University |
| ClinicalTrials.gov Identifier: | NCT00067860 |
Purpose
This is a double-blind randomized controlled study on the clinical and metabolic effects and underlying gut mucosal mechanisms of modified diet, with or without recombinant human growth hormone, in adults with severe short bowel syndrome dependent upon parenteral nutrition. Clinical endpoints include ability to wean patients from parenteral feeding, metabolic endpoints include gut nutrient absorptive function and molecular endpoints include expression of growth factors and nutrient transporters in small bowel and colonic mucosa. The 6-month study is performed, in part, in the General Clinical Research Center for inpatient stays and outpatient visits.
| Condition | Intervention | Phase |
|---|---|---|
|
Short Bowel Syndrome |
Drug: recombinant human growth hormone Behavioral: diet modification |
Phase II |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Diet/Growth Factor Mechanisms of Gut Adaptation |
| Estimated Enrollment: | 30 |
| Study Start Date: | October 1996 |
| Study Completion Date: | December 2006 |
| Primary Completion Date: | December 2006 (Final data collection date for primary outcome measure) |
This is a double-blind randomized controlled study on the clinical and metabolic effects and underlying gut mucosal mechanisms of modified diet, with or without recombinant human growth hormone, in adults with severe short bowel syndrome dependent upon parenteral nutrition. Clinical endpoints include ability to wean patients from parenteral feeding, metabolic endpoints include gut nutrient absorptive function and molecular endpoints include expression of growth factors and nutrient transporters in small bowel and colonic mucosa. The 6-month study is performed, in part, in the General Clinical Research Center for inpatient stays and outpatient visits.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Contacts and Locations| United States, Georgia | |
| Emory University School of Medicine | |
| Atlanta, Georgia, United States, 30322 | |
| Principal Investigator: | Thomas R Ziegler, MD | Emory University |
More Information
| ClinicalTrials.gov Identifier: | NCT00067860 History of Changes |
| Other Study ID Numbers: | DK55850, R01DK055850, DK55850 |
| Study First Received: | August 29, 2003 |
| Last Updated: | June 23, 2011 |
| Health Authority: | United States: Food and Drug Administration |
|
Short Bowel Syndrome Malabsorption Syndromes Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases Postoperative Complications Pathologic Processes |
Mitogens Hormones Mitosis Modulators Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |